Tag: Brentuximab Vedotin

As the premier hematology event in malignant and non-malignant hematology, the annual meeting of the American Society of Hematology (ASH), held this year from...

Seattle Genetics has submitted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) to the U.S. Food and Drug Administration (FDA). The submission is...

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

Antibody-drug conjugates or ADCs, which link an antibody to a potent, small-molecule, cytotoxic, cell-killing, chemotherapeutic agent, use the target-specificity of monoclonal antibodies or antibody...

This year, the American Association for Cancer Research (AACR) will host their annual meeting April 14 - 18, 2018 in the McCormick Place North/South...

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with chemotherapy in adult patients with previously untreated...

The European Commission has extended the current conditional marketing authorization for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include the treatment of adult patients with...

Antibody-drug conjugates or ADCs have emerged as a powerful and strategy tool in the targeted treatment of cancer.  These relatively novel agents combine the...

Based on positive results from the Phase III ECHELON-1 clinical trial, the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental...

Data from the Phase III ECHELON-1 clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics | Takeda) as part of a frontline combination chemotherapy regimen...